Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haploidentical natural killer cells + epacadostat + interleukin-2
- Development stage
- Unknown
- Lead developer
- Masonic Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intraperitoneal, Oral
01
Overview
This investigational combination therapy, developed by the Masonic Cancer Center at the University of Minnesota, consists of allogeneic haploidentical natural killer (NK) cells, the IDO1 inhibitor epacadostat (INCB024360), and interleukin-2 (IL-2). It is specifically designed for the treatment of recurrent ovarian, fallopian tube, and primary peritoneal cancers. The regimen involves the intraperitoneal administration of donor-derived NK cells to provide direct anti-tumor activity within the peritoneal cavity. Epacadostat is administered orally to block the immunosuppressive effects of the IDO1 enzyme, which is often overexpressed in these tumors to inhibit immune responses. Interleukin-2 is co-administered intraperitoneally to enhance the survival, persistence, and cytotoxic function of the infused NK cells. This approach aims to overcome the immunosuppressive tumor microenvironment and leverage the innate anti-tumor capabilities of NK cells.
- Other names
- Epacadostat and IP NK Cells for Recurrent Ovarian CancerNK cells + INCB024360 + IL-2
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on haploidentical natural killer cells + epacadostat + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haploidentical natural killer cells + epacadostat + interleukin-2.